Biden Administration Pause On Pending Trump-Era Rules Stalls FDA Cannabinoids Guidance Progress

Waiting for the US Food and Drug Administration to publish a draft guidance on cannabidiol enforcement? The wait grows longer with the withdrawal of the document along with other pending FDA regulatory items from the White House review process.

President Biden’s chief of staff on 20 January advised the Office of Management and Budget to withdraw from the executive agency’s review any pending rule or other regulatory item, including guidance documents, submitted by all federal agencies. The